Fiche centre
Mount Sinai School of Medicine
New York — United States
Essais liés12clinical trials
VilleNew Yorklocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT00003595
Essais cliniques associés
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NLY01 | SEP | Phase 2 | NCT07497399 | TAG-MS — Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis | RECRUITING |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 4 | NCT06909565 | V-INTERVENTION — Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | RECRUITING |
| Filgrastim | SEP | Phase 3 | NCT00003595 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma | COMPLETED |
| Nicotine Transdermal Patch | Alzheimer | Phase 2 | NCT02720445 | Memory Improvement Through Nicotine Dosing (MIND) Study | COMPLETED |
| Ribociclib | Cancer | Phase 3 | NCT05827081 | Adjuvant WIDER — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | RECRUITING |
| Low Dose Benfotiamine | Alzheimer | Phase 2 | NCT06223360 | A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | ACTIVE_NOT_RECRUITING |
| Solanezumab | Alzheimer | Phase 3 | NCT02008357 | A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss | COMPLETED |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| CT1812 | Alzheimer | Phase 2 | NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | Alzheimer | À vérifier | NCT01078636 | ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | COMPLETED |
| Plerixafor | Cancer | NA | NCT01042717 | Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | UNKNOWN |
| eculizumab | Myasthénie | Phase 2 | NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | TERMINATED |